

19 October 2016

Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)

Genetic Signatures Limited (ASX:GSS) (**Genetic Signatures**) has today issued 18,886,074 fully paid ordinary shares (**Shares**) to certain sophisticated and institutional investors in Australia and in certain overseas jurisdictions under a placement approved by shareholders on 13 October 2016.

In accordance with the requirements of Section 708A(6) of the Corporations Act 2001 (Cth) (**Corporations Act**), Genetic Signatures gives ASX notice that:

- (a) The Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
- (b) This notice is being given under paragraph 5(e) of Section 708A of the Corporations Act.
- (c) As at the date of this notice, Genetic Signatures has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to it; and
 - (ii) Section 674 of the Corporations Act.
- (d) As at the date of this notice, there is no excluded information (as defined in Section 708A(7) and (8) of the Corporations Act).

For further information, see our website (<u>www.geneticsignatures.com</u>) or contact us as below:

Company	Media and Investor Relations
John Melki	Peter Taylor
Chief Executive Officer	Investor Relations
john@geneticsignatures.com	peter@nwrcommunications.com.au
T: +61 2 9870 7580	T: +61 412 036 231

▶ Phone: +61 2 9870 7580 Fax: +61 2 9889 4034

Email: info@geneticsignatures.com

Web: geneticsignatures.com